Literature DB >> 10721994

Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses.

T B Geijtenbeek1, R Torensma, S J van Vliet, G C van Duijnhoven, G J Adema, Y van Kooyk, C G Figdor.   

Abstract

Contact between dendritic cells (DC) and resting T cells is essential to initiate a primary immune response. Here, we demonstrate that ICAM-3 expressed by resting T cells is important in this first contact with DC. We discovered that instead of the common ICAM-3 receptors LFA-1 and alphaDbeta2, a novel DC-specific C-type lectin, DC-SIGN, binds ICAM-3 with high affinity. DC-SIGN, which is abundantly expressed by DC both in vitro and in vivo, mediates transient adhesion with T cells. Since antibodies against DC-SIGN inhibit DC-induced proliferation of resting T cells, our findings predict that DC-SIGN enables T cell receptor engagement by stabilization of the DC-T cell contact zone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10721994     DOI: 10.1016/s0092-8674(00)80693-5

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  481 in total

Review 1.  In vivo maturation and migration of dendritic cells.

Authors:  L Flores-Romo
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

2.  An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus.

Authors:  S Gummuluru; C M Kinsey; M Emerman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 3.  Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.

Authors:  Ralph Marvin Steinman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

Review 4.  Imaging T-cell antigen recognition and comparing immunological and neuronal synapses.

Authors:  E Donnadieu; P Revy; A Trautmann
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

5.  Unique appearance of proliferating antigen-presenting cells expressing DC-SIGN (CD209) in the decidua of early human pregnancy.

Authors:  Ulrike Kämmerer; Andreas O Eggert; Michaela Kapp; Alexander D McLellan; Teunis B H Geijtenbeek; Johannes Dietl; Yvette van Kooyk; Eckhart Kämpgen
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

6.  Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Authors:  Eynav Klechevsky; Anne-Laure Flamar; Yanying Cao; Jean-Philippe Blanck; Maochang Liu; Amy O'Bar; Olivier Agouna-Deciat; Peter Klucar; Luann Thompson-Snipes; Sandra Zurawski; Yoram Reiter; A Karolina Palucka; Gerard Zurawski; Jacques Banchereau
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

7.  Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas.

Authors:  Motohiro Nonaka; Bruce Yong Ma; Hirotsugu Imaeda; Keiko Kawabe; Nobuko Kawasaki; Keiko Hodohara; Nana Kawasaki; Akira Andoh; Yoshihide Fujiyama; Toshisuke Kawasaki
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

8.  C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.

Authors:  Carmen P Alvarez; Fátima Lasala; Jaime Carrillo; Oscar Muñiz; Angel L Corbí; Rafael Delgado
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN.

Authors:  Cinzia Nobile; Arnaud Moris; Françoise Porrot; Nathalie Sol-Foulon; Olivier Schwartz
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

10.  Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins.

Authors:  Mary Requena; Hicham Bouhlal; Nadine Nasreddine; Hela Saidi; Jean-Chrysostome Gody; Sylvie Aubry; Gérard Grésenguet; Michel D Kazatchkine; Rafick-Pierre Sekaly; Laurent Bélec; Hakim Hocini
Journal:  Immunology       Date:  2007-11-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.